Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Data Brief ; 52: 109999, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38226035

RESUMEN

In the pursuit of advancing research in continuous user authentication, we introduce COUNT-OS-I and COUNT-OS-II, two distinct performance counter datasets from Windows operating systems, crafted to bolster research in continuous user authentication. Encompassing data from 63 computers and users, the datasets offer rich, real-world insights for developing and evaluating authentication models. COUNT-OS-I spans 26 users in an IT department, capturing 159 attributes across diverse hardware and software environments over 26 h on average per user. COUNT-OS-II, on the other hand, encompasses 37 users with identical system configurations, recording 218 attributes per sample over a 48-hour period. Both datasets utilize pseudonymization to safeguard user identities while maintaining data integrity and statistical accuracy. The well-balanced nature of the data, confirmed by comprehensive statistical analysis, positions these datasets as reliable benchmarks for the continuous user authentication domain. Through their release, we aim to empower the development of robust, real-world applicable authentication models, contributing to enhanced system security and user trust.

2.
Data Brief ; 51: 109750, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38020437

RESUMEN

High-quality datasets are crucial for building realistic and high-performance supervised malware detection models. Currently, one of the major challenges of machine learning-based solutions is the scarcity of datasets that are both representative and of high quality. To foster future research and provide updated and public data for comprehensive evaluation and comparison of existing classifiers, we introduce the MH-100K dataset [1], an extensive collection of Android malware information comprising 101,975 samples. It encompasses a main CSV file with valuable metadata, including the SHA256 hash (APK's signature), file name, package name, Android's official compilation API, 166 permissions, 24,417 API calls, and 250 intents. Moreover, the MH-100K dataset features an extensive collection of files containing useful metadata of the VirusTotal1 analysis. This repository of information can serve future research by enabling the analysis of antivirus scan result patterns to discern the prevalence and behaviour of various malware families. Such analysis can help to extend existing malware taxonomies, the identification of novel variants, and the exploration of malware evolution over time.

3.
Sci Rep ; 12(1): 15149, 2022 09 07.
Artículo en Inglés | MEDLINE | ID: mdl-36071135

RESUMEN

Phishing is an attack characterized by attempted fraud against users. The attacker develops a malicious page that is a trusted environment, inducing its victims to submit sensitive data. There are several platforms, such as PhishTank and OpenPhish, that maintain databases on malicious pages to support anti-phishing solutions, such as, for example, block lists and machine learning. A problem with this scenario is that many of these databases are disorganized, inconsistent, and have some limitations regarding integrity and balance. In addition, because phishing is so volatile, considerable effort is put into preserving temporal information from each malicious page. To contribute, this article built a phishing database with consistent and balanced data, temporal information, and a significant number of occurrences, totaling 942,471 records over the 5 years between 2016 and 2021. Of these records, 135,542 preserve the page's source code, 258,416 have the attack target brand detected, 70,597 have the hosting service identified, and 15,008 have the shortener service discovered. Additionally, 123,285 records store WHOIS information of the domain registered in 2021. The data is available on the website https://piracema.io/repository.


Asunto(s)
Seguridad Computacional , Programas Informáticos , Bases de Datos Factuales , Fraude , Confianza
4.
Int J Med Sci ; 17(14): 2133-2146, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32922174

RESUMEN

The SARS-CoV-2 spread quickly across the globe. The World Health Organization (WHO) on March 11 declared COVID-19 a pandemic. The mortality rate, hospital disorders and incalculable economic and social damages, besides the unproven efficacy of the treatments evaluated against COVID-19, raised the need for immediate control of this disease. Therefore, the current study employed in silico tools to rationally identify new possible SARS-CoV-2 main protease (Mpro) inhibitors. That is an enzyme conserved among the coronavirus species; hence, the identification of an Mpro inhibitor is to make it a broad-spectrum drug. Molecular docking studies described the binding sites and the interaction energies of 74 Mpro-ligand complexes deposited in the Protein Data Bank (PDB). A structural similarity screening was carried out in order to identify possible Mpro ligands that show additional pharmacological properties against COVID-19. We identified 59 hit compounds and among them, melatonin stood out due to its prominent immunomodulatory and anti-inflammatory activities; it can reduce oxidative stress, defence cell mobility and efficiently combat the cytokine storm and sepsis. In addition, melatonin is an inhibitor of calmodulin, an essential intracellular component to maintain angiotensin-converting enzyme 2 (ACE-2) on the cell surface. Interestingly, one of the most promising hits in our docking study was melatonin. It revealed better interaction energy with Mpro compared to ligands in complexes from PDB. Consequently, melatonin can have response potential in early stages for its possible effects on ACE-2 and Mpro, although it is also promising in more severe stages of the disease for its action against hyper-inflammation. These results definitely do not confirm antiviral activity, but can rather be used as a basis for further preclinical and clinical trials.


Asunto(s)
Infecciones por Coronavirus/tratamiento farmacológico , Descubrimiento de Drogas , Melatonina/farmacología , Neumonía Viral/tratamiento farmacológico , Proteínas no Estructurales Virales/antagonistas & inhibidores , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Antioxidantes/farmacología , Antioxidantes/uso terapéutico , Betacoronavirus/metabolismo , Betacoronavirus/patogenicidad , COVID-19 , Proteasas 3C de Coronavirus , Infecciones por Coronavirus/virología , Cisteína Endopeptidasas , Humanos , Factores Inmunológicos/farmacología , Factores Inmunológicos/uso terapéutico , Melatonina/uso terapéutico , Simulación del Acoplamiento Molecular , Pandemias , Neumonía Viral/virología , Inhibidores de Proteasas/farmacología , Inhibidores de Proteasas/uso terapéutico , SARS-CoV-2 , Tratamiento Farmacológico de COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA